LARIMAR THERAPEUTICS INC (LRMR) Stock Fundamental Analysis

NASDAQ:LRMR • US5171251003

5.31 USD
-0.21 (-3.8%)
At close: Feb 27, 2026
5.14 USD
-0.17 (-3.2%)
After Hours: 2/27/2026, 8:16:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall LRMR gets a fundamental rating of 2 out of 10. We evaluated LRMR against 521 industry peers in the Biotechnology industry. The financial health of LRMR is average, but there are quite some concerns on its profitability. LRMR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year LRMR has reported negative net income.
  • LRMR had a negative operating cash flow in the past year.
  • LRMR had negative earnings in each of the past 5 years.
  • LRMR had a negative operating cash flow in each of the past 5 years.
LRMR Yearly Net Income VS EBIT VS OCF VS FCFLRMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -70.46%, LRMR is doing worse than 62.76% of the companies in the same industry.
  • LRMR has a Return On Equity (-94.94%) which is in line with its industry peers.
Industry RankSector Rank
ROA -70.46%
ROE -94.94%
ROIC N/A
ROA(3y)-35.58%
ROA(5y)-42.34%
ROE(3y)-41.34%
ROE(5y)-50%
ROIC(3y)N/A
ROIC(5y)N/A
LRMR Yearly ROA, ROE, ROICLRMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • LRMR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LRMR Yearly Profit, Operating, Gross MarginsLRMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for LRMR has been increased compared to 1 year ago.
  • The number of shares outstanding for LRMR has been increased compared to 5 years ago.
  • There is no outstanding debt for LRMR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LRMR Yearly Shares OutstandingLRMR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
LRMR Yearly Total Debt VS Total AssetsLRMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • LRMR has an Altman-Z score of 1.34. This is a bad value and indicates that LRMR is not financially healthy and even has some risk of bankruptcy.
  • With a decent Altman-Z score value of 1.34, LRMR is doing good in the industry, outperforming 63.72% of the companies in the same industry.
  • LRMR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.34
ROIC/WACCN/A
WACCN/A
LRMR Yearly LT Debt VS Equity VS FCFLRMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 4.06 indicates that LRMR has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.06, LRMR is in line with its industry, outperforming 48.56% of the companies in the same industry.
  • LRMR has a Quick Ratio of 4.06. This indicates that LRMR is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of LRMR (4.06) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.06
Quick Ratio 4.06
LRMR Yearly Current Assets VS Current LiabilitesLRMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • LRMR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -67.83%.
EPS 1Y (TTM)-67.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-154.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -6.79% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-53.18%
EPS Next 2Y-19.44%
EPS Next 3Y-6.72%
EPS Next 5Y-6.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LRMR Yearly Revenue VS EstimatesLRMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
LRMR Yearly EPS VS EstimatesLRMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • LRMR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LRMR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LRMR Price Earnings VS Forward Price EarningsLRMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LRMR Per share dataLRMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • LRMR's earnings are expected to decrease with -6.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.44%
EPS Next 3Y-6.72%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • LRMR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LARIMAR THERAPEUTICS INC

NASDAQ:LRMR (2/27/2026, 8:16:03 PM)

After market: 5.14 -0.17 (-3.2%)

5.31

-0.21 (-3.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-18
Inst Owners102.14%
Inst Owner Change-10.97%
Ins Owners1.05%
Ins Owner Change4.63%
Market Cap441.21M
Revenue(TTM)N/A
Net Income(TTM)-132.00M
Analysts89.41
Price Target15.5 (191.9%)
Short Float %10.89%
Short Ratio7.8
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.87%
Min EPS beat(2)-48.03%
Max EPS beat(2)16.29%
EPS beat(4)1
Avg EPS beat(4)-19.67%
Min EPS beat(4)-48.03%
Max EPS beat(4)16.29%
EPS beat(8)2
Avg EPS beat(8)-10.27%
EPS beat(12)6
Avg EPS beat(12)-0.43%
EPS beat(16)10
Avg EPS beat(16)4.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.63%
PT rev (3m)-8.63%
EPS NQ rev (1m)2.36%
EPS NQ rev (3m)1.82%
EPS NY rev (1m)0.6%
EPS NY rev (3m)-17.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.17
P/tB 3.17
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)-1.85
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS1.67
TBVpS1.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.46%
ROE -94.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.58%
ROA(5y)-42.34%
ROE(3y)-41.34%
ROE(5y)-50%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 79.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.06
Quick Ratio 4.06
Altman-Z 1.34
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)82.04%
Cap/Depr(5y)77.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-154.17%
EPS Next Y-53.18%
EPS Next 2Y-19.44%
EPS Next 3Y-6.72%
EPS Next 5Y-6.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-89.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-71.02%
EBIT Next 3Y-22.03%
EBIT Next 5Y25.77%
FCF growth 1Y-214.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-213.4%
OCF growth 3YN/A
OCF growth 5YN/A

LARIMAR THERAPEUTICS INC / LRMR FAQ

What is the fundamental rating for LRMR stock?

ChartMill assigns a fundamental rating of 2 / 10 to LRMR.


What is the valuation status for LRMR stock?

ChartMill assigns a valuation rating of 0 / 10 to LARIMAR THERAPEUTICS INC (LRMR). This can be considered as Overvalued.


What is the profitability of LRMR stock?

LARIMAR THERAPEUTICS INC (LRMR) has a profitability rating of 0 / 10.


What is the earnings growth outlook for LARIMAR THERAPEUTICS INC?

The Earnings per Share (EPS) of LARIMAR THERAPEUTICS INC (LRMR) is expected to decline by -53.18% in the next year.